Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors

Beth Snyder Bulik

Senior Editor

A federal judge invalidated four of Vanda Pharmaceuticals’ patents for sleep med Hetlioz on Tuesday, effectively opening the door to generic tasimelteon competition from Teva …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Van­da los­es Het­lioz patent court de­ci­sion, vows to ap­peal and ask for stay on Te­va, Apo­tex com­peti­tors

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors